March 20, 2018 / 6:19 AM / a month ago

BRIEF-Santhera Pharmaceuticals FY ‍Net Result At CHF -51.5 Mln

March 20 (Reuters) - SANTHERA PHARMACEUTICALS HOLDING AG :

* SANTHERA PHARMACEUTICALS - FY ‍NET REVENUES FROM SALES OF LEAD PRODUCT RAXONE® INCREASED BY 21% TO CHF 22.9 MILLION​

* FY ‍NET RESULT AMOUNTED TO CHF -51.5 MILLION (2016: CHF -35.4 MILLION)​

* SANTHERA PHARMACEUTICALS - ‍AT END OF FEB 2018, COMPANY HAD CASH, CASH EQUIVALENTS AND SHORT-TERM FINANCIAL ASSETS OF CHF 50.9 MILLION​

* SANTHERA - ‍REITERATES GUIDANCE FOR NET SALES OF RAXONE IN CURRENTLY APPROVED INDICATION LHON TO REACH CHF 28-30 MILLION IN 2018​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below